Carvedilol

Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

Product Specifications

CAS Number

[72956-09-3]

Product Name Alternative

BM 14190

UNSPSC

12352005

Hazard Statement

H410

Target

Adrenergic Receptor; Autophagy; Bacterial

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/carvedilol.html

Concentration

10mM

Purity

99.98

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(CNCCOC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4

Molecular Formula

C24H26N2O4

Molecular Weight

406.47

Precautions

H410

References & Citations

[1]Eggertsen R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol. 1984;27 (1) :19-22.|[2]Feuerstein GZ, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl. 1993 Jun;11 (4) :S41-8.|[3]Wong WT, et al. Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. Front Immunol. 2018 Aug 22;9:1920.